DK1309324T3 - Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X - Google Patents

Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X

Info

Publication number
DK1309324T3
DK1309324T3 DK01958878T DK01958878T DK1309324T3 DK 1309324 T3 DK1309324 T3 DK 1309324T3 DK 01958878 T DK01958878 T DK 01958878T DK 01958878 T DK01958878 T DK 01958878T DK 1309324 T3 DK1309324 T3 DK 1309324T3
Authority
DK
Denmark
Prior art keywords
convulsive
syndrome
prevention
treatment
type
Prior art date
Application number
DK01958878T
Other languages
Danish (da)
English (en)
Inventor
Carlos Plata-Salaman
Jeffrey Crooke
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1309324T3 publication Critical patent/DK1309324T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01958878T 2000-07-07 2001-07-06 Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X DK1309324T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US27002201P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
DK1309324T3 true DK1309324T3 (da) 2006-06-12

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01958878T DK1309324T3 (da) 2000-07-07 2001-07-06 Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X

Country Status (22)

Country Link
US (2) US6852701B2 (enExample)
EP (1) EP1309324B1 (enExample)
JP (1) JP4920163B2 (enExample)
CN (1) CN101404993A (enExample)
AR (1) AR032465A1 (enExample)
AT (1) ATE320805T1 (enExample)
AU (1) AU2001280486A1 (enExample)
BR (1) BR0112519A (enExample)
CA (1) CA2415093A1 (enExample)
DE (1) DE60118206T2 (enExample)
DK (1) DK1309324T3 (enExample)
ES (1) ES2260261T3 (enExample)
HU (1) HUP0302307A3 (enExample)
IL (1) IL153713A0 (enExample)
MX (1) MXPA03000136A (enExample)
MY (1) MY126897A (enExample)
NO (1) NO20030064L (enExample)
NZ (1) NZ523531A (enExample)
PL (1) PL365680A1 (enExample)
PT (1) PT1309324E (enExample)
RU (1) RU2268720C2 (enExample)
WO (1) WO2002003984A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7208477B2 (en) 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
JP2009537635A (ja) 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN102114002B (zh) * 2006-12-04 2016-05-11 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
AU2008209320B2 (en) * 2007-01-25 2013-05-30 NAIA Metabolic, Inc. Insulin sensitisers and methods of treatment
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
JP6055076B2 (ja) 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー.エル.エー.チャイナ シネフリン及びトピラマートを含む組み合わせ製品
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
SK284305B6 (sk) * 1996-06-28 2005-01-03 Ortho-Mcneil Pharmaceutical, Inc. Liečivo na liečbu obezity
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
ES2238999T3 (es) 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
US6191163B1 (en) * 1999-04-08 2001-02-20 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
NZ514811A (en) 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
WO2000076493A1 (en) * 1999-06-14 2000-12-21 Thomas Najarian Combination therapy for effecting weight loss and treating obesity

Also Published As

Publication number Publication date
PT1309324E (pt) 2006-06-30
DE60118206D1 (de) 2006-05-11
WO2002003984A2 (en) 2002-01-17
US20040209824A1 (en) 2004-10-21
HUP0302307A3 (en) 2007-05-29
JP4920163B2 (ja) 2012-04-18
HUP0302307A2 (hu) 2003-10-28
EP1309324B1 (en) 2006-03-22
NO20030064L (no) 2003-03-06
US7109174B2 (en) 2006-09-19
MY126897A (en) 2006-10-31
PL365680A1 (en) 2005-01-10
WO2002003984A3 (en) 2003-03-06
EP1309324A2 (en) 2003-05-14
IL153713A0 (en) 2003-07-06
US6852701B2 (en) 2005-02-08
MXPA03000136A (es) 2004-09-13
CN101404993A (zh) 2009-04-08
AR032465A1 (es) 2003-11-12
AU2001280486A1 (en) 2002-01-21
NZ523531A (en) 2005-07-29
JP2004510700A (ja) 2004-04-08
ATE320805T1 (de) 2006-04-15
ES2260261T3 (es) 2006-11-01
RU2268720C2 (ru) 2006-01-27
CA2415093A1 (en) 2002-01-17
NO20030064D0 (no) 2003-01-06
DE60118206T2 (de) 2006-12-14
US20020037861A1 (en) 2002-03-28
BR0112519A (pt) 2004-03-30

Similar Documents

Publication Publication Date Title
NO20030064D0 (no) Antikonvulsive derivater for anvendelse ved prevensjon av utvikling av typeII diabetes mellitus og syndrom X
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1183020T3 (da) (3-trihalogenmethylphenoxy)(4-halogenphenyl) til behandling af insulinresistens og type 2-diabetes
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO20016314D0 (no) Blandinger og fremgangsmåte for oljefeltapplikasjoner
NO20043733L (no) Aryl-5-tio-Β-D-glukopyranosid-derivater og legemidler for diabetes inneholdende de samme
NL1016224A1 (nl) Foto-basevormend middel en foto-zuurvormend middel bevattende foto- etssamenstelling.
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
DK1143977T3 (da) 2-oxy-benzoxazinonderivater til behandling af obesitas
ATE297920T1 (de) Linezolid-krystall form ii
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
DK1282719T3 (da) Fremgangsmåde til fremstilling af dihydroxyestere og derivater deraf
NO20030800L (no) Aminoalkylbenzoyl-benzofuran- eller benzotiofenderivater, fremgangsmåte forderes fremstilling og preparater inneholdende de samme
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DK1228193T3 (da) Felint calicivirirus-gener og rekombinante vacciner der indeholder dem
NO20030759D0 (no) 10-aryl-11-HBENZO(b)fluorenderivater og analoger for medisinsk anvendelse
NO20035056D0 (no) Adenosinanaloger for behandling av insulinresistenssyndrom og diabetes
NO20011537D0 (no) Kjemokinreseptorpeptidvaksiner for behandling og forebygging av diabetes
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
DE50112350D1 (de) Arzneimittel enthaltend aktiviertes antithrombin iii
DK1173436T3 (da) Thiazolidindionderivat og anvendelse deraf som antidiabetikum
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini